Rosiglitazone
An anti-diabetic drug can inhibit the growth of melanoma in older patients by activating an anti-aging gene that in turn inhibits a protein involved in metastatic progression and resistance to targeted therapies for the disease. Even more than other types of cancer, melanoma is a disease of aging, with older patients more frequently diagnosed with the disease and having a worse prognosis. Targeted therapies have brought benefits in terms of overall survival compared to chemotherapy but they are limited by intrinsic or acquired resistance.
Wistar scientists have previously shown that age-related changes in the tumor microenvironment – or the surrounding area where tumor cells crosstalk with normal and immune cells – can drive melanoma progression and therapy resistance...
Read More
Recent Comments